Advanced Protein Production

Advanced Protein Production focuses on overcoming the technical hurdles associated with producing high-value, difficult-to-express proteins, including antibodies, enzymes, and membrane proteins. Its core technology platform aims to increase yields, improve stability, and ensure proper folding of biologics, which are critical for advancing novel therapeutics. The company operates through a hybrid business model, advancing its own preclinical pipeline while offering contract development and manufacturing services. Its strategic direction involves leveraging its platform to forge partnerships with larger biopharma companies and progress its most promising internal candidates toward clinical development.

A proprietary, multi-host protein expression and purification platform specifically engineered for the high-yield production of complex, difficult-to-manufacture recombinant proteins, including antibodies, enzymes, and membrane proteins.

APP faces competition from large-scale CDMOs (e.g., Lonza, Catalent) and other platform biotechs specializing in protein expression. Its differentiation hinges on a focused claim of superior capability with the most challenging protein targets, offering a potentially faster and more reliable path for partners stuck on manufacturability issues.